Zhejiang Better Pharmaceuticals Co. Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation finerenone tablets (specification: 20 mg, produced by Zhejiang Beide Pharmaceutical Co., Ltd.) and the reference preparation finerenone tablets (trade name: Kerendia®; specification: 20 mg; produced by Bayer AG) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study is to evaluate the safety of the test preparation finerenone tablets (specification: 20 mg) and the reference preparation finerenone tablets (trade name: Kerendia®, specification: 20 mg) in healthy subjects.

To investigate the pharmacokinetic characteristics of a single oral dose of lacidipine tablets (test preparation T, strength: 6 mg) provided by Zhejiang Beide Pharmaceutical Co., Ltd. and a single oral dose of lacidipine tablets (reference preparation R, trade name: Lacipil®, strength: 6 mg) certified by GlaxoSmithKline S.p.A. in healthy subjects under postprandial conditions, evaluate the bioequivalence and safety of the two preparations, and provide a basis for the registration application of the test preparation.

To investigate the pharmacokinetic characteristics of a single oral administration of azithromycin dispersible tablets produced by Zhejiang Beide Pharmaceutical Co., Ltd. (test preparation T, specification: 0.25 g) and a single oral administration of azithromycin tablets certified by Teva Nederland B.V. (reference preparation R, trade name: Azitromycin 250 mg TEVA, specification: 0.25 g) in healthy subjects under fasting and postprandial conditions, and to evaluate the bioequivalence and safety of the two preparations.